Eravacycline: from clinical trials to its potential place in everyday therapy

The ongoing emergence of multidrug-resistant (MDR) pathogens represents a major challenge in clinical practice, highlighting the need of novel antimicrobial agents. Eravacycline, a synthetic fluorocycline, has shown potent in-vitro activity against a broad spectrum of Gram-positive, Gram-negative, and anaerobic pathogens. This review aims to summarize the antimicrobial profile, pharmacokinetics, clinical efficacy, and safety of eravacyclineand and explores its potential applications in routine clinical practice.

Eravacycline has been approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of complicated intra-abdominal infections (cIAIs). Phase III clinical trials (IGNITE 1 and IGNITE 4) have demonstrated its noninferiority to carbapenems for cIAIs, with a favorable safety profile. Real-world evidence indicates that eravacycline is increasingly used for infections beyond its approved indications, including pneumonia, bloodstream infections, and skin and soft tissue infections. In-vitro studies indicate strong activity against Enterobacterales, carbapenem-resistant Enterobacterales and Acinetobacter baumannii, as well as vancomycin-resistant Enterococcus, supporting its potential role for difficult-to-treat infections.

While clinical data remain limited, eravacycline appears promising for the treatment of infections caused by MDR pathogens, particularly in patients with limited therapeutic options or intolerance to β-lactams. As resistance mechanisms continue to evolve, the role of eravacycline in real-world clinical practice may extend beyond its current indications, warranting further research to define its optimal therapeutic applications.